by admin | Jan 9, 2026 | press-releases
Home PRESS RELEASE CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== -->...
by admin | Jan 6, 2026 | press-releases
Home CG Oncology to Present… PRESS RELEASE CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== -->...
by admin | Dec 18, 2025 | press-releases
Home PRESS RELEASE SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | Dec 5, 2025 | press-releases
Home PRESS RELEASE New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO...
by admin | Nov 25, 2025 | press-releases
Home PRESS RELEASE CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | Apr 26, 2025 | press-releases
Home PRESS RELEASE CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting 💻 DESKTOP AUDIO PLAYER...